if market can take gilead to P/E of 8, this can go down to 200-220.... will jump back once see some price stablization..
true....they are killing medical innovation... ,most of the companies especially small biotech will run our of equity/capital to fund..which will impact research.. wait until they get uncurable cancer!!!....bloody dem·a·gogue
Spoke Friday evening with investor analyst@KMI .. Announce plans for 2016.. Dividend will be frozen , possible some asset sales ..in my view KMI should stabling in low 20s if oil remains in this range..
Remember it was $90 stock in Nov-Dec2014 before Biomarin acquired this useless drug..sales of other drugs have gone up and pipeline advance, so at this point, market is accounting for Zero probability of approval.
Biomarin will trade with IBB biotech index going fwd...it is like 40% down from its summer highs..
I won't be short this stock at this price. mid-90s...not much downside. always a chance of M&A and surprise. it can rip upwards..
BOA Merrill Positive on results..
are u listening to conf call?.. they might have cure for MS with anti-lingo........................
as investor have time frame for few months... when market sells.. quality companies with earnings growth $7.2 eps in FY16 will hold..then go up..
Today all short term money cap out..its call PROFIT BOOKING...same short term money will be back..u can also buy AET and ANTM.. way undervalued
yeah...dem's can't be seen as negative to biotech end of the day...they represent innovation, progressive new economy,,
sanders is socialist,..when these politicians have cancer,,they will need all these medical innovations....
or computer algorithsm
...5 out of 100 go past phase 3 .....
Hillary Clinton are u listening..?
..biotech is now selective..CELG , AMGN, GILD....
Biogen out.. unless earnings show stability .. very low expectation.. big funds are selling .. they got burned last 2 times
We view Roche’s data in PPMS as potential upside for BIIB as BIIB will receive tiered royalties between 13.5% and 24% on US sales of ocrelizumab, if approved. BofAML Roche analyst estimates peak sales of ocrelizumab across PPMS and RRMS of CHF7B. The potential revenue stream could add nicely to BIIB’s top and bottom line; we maintain our Buy rating and PO of $400
so from 20% of $7 Billiobn peak adds another $1.5 revenue....
..AGN or PFE will be good fit...